Semaglutide is a glucagon-like peptide-1 receptor agonist that mirrors the action of GLP-1 in the body. GLP-1 regulates appetite, blood sugar, and insulin release. Semaglutide's activation of GLP-1 receptors leads to increased insulin secretion, decreased glucagon production, slower stomach emptying, and reduced food intake. This multifaceted approach contributes to weight loss.
Trizepatide mimics the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, prompting insulin secretion, also by helping the patient feel full with less food, and slowing the passage of food through the digestive tract.
Studies have shown that Semaglutide can lead to significant weight loss when combined with diet and exercise. Users have reported positive outcomes in terms of both pounds lost and improvements in other health markers.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.